Lipschütz ulcer following first dose of COVID-19 tozinameran vaccine: Report of a case and review of a World Health Organization pharmacovigilance database.

Autor: Ewig E; Department of Pharmacology and Pharmacovigilance Center of Nice, University Hospital of Nice, Nice, France., Ben Othman N; Department of Pharmacology and Pharmacovigilance Center of Nice, University Hospital of Nice, Nice, France., Viard D; Department of Pharmacology and Pharmacovigilance Center of Nice, University Hospital of Nice, Nice, France., Gauci PA; Department of Gynecology, University Hospital of Nice, Nice, France., Rocher F; Department of Pharmacology and Pharmacovigilance Center of Nice, University Hospital of Nice, Nice, France., Drici MD; Department of Pharmacology and Pharmacovigilance Center of Nice, University Hospital of Nice, Nice, France.
Jazyk: angličtina
Zdroj: International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics [Int J Gynaecol Obstet] 2024 Oct 23. Date of Electronic Publication: 2024 Oct 23.
DOI: 10.1002/ijgo.15941
Abstrakt: Lipschütz ulcer (LU) is a condition known for painful vulvar ulcers, typically affecting young women and often linked to infectious agents. Recent reports have indicated a potential connection between LU and COVID-19 vaccination, particularly after the second or booster doses. This study presents a case of LU following the first dose of tozinameran in a young woman who had a previous SARS-CoV-2 infection and investigates similar cases globally. An 18-year-old woman experienced vulvar pain and ulcers 2-days after her initial COVID-19 vaccine dose. After ruling out infections through serological tests, a diagnosis of LU was made, and her symptoms resolved after 10 days. A literature search and VigiBase® analysis revealed 11 cases of LU following COVID-19 vaccination, and 519 vulvovaginal ulcer cases associated with these vaccines were identified in Vigibase®, with a median onset of 2 days. Most LU cases occurred after the second dose or booster shots. The primary hypothesis for this association is a type 3 hypersensitivity reaction mediated by immune complexes, possibly triggered by prior exposure, as many cases occurred after the second dose. Interestingly, the presented case suggests that prior COVID-19 infection could serve as sensitization. In conclusion, this study highlights the potential occurrence of LU after the initial COVID-19 vaccine dose in young patients with prior COVID-19 infection. While the risk of recurrence after subsequent vaccinations or infections remains uncertain, the benefits of vaccination outweigh the risks. Clinicians and patients should be aware of this potential issue to make informed decisions regarding vaccination.
(© 2024 The Author(s). International Journal of Gynecology & Obstetrics published by John Wiley & Sons Ltd on behalf of International Federation of Gynecology and Obstetrics.)
Databáze: MEDLINE
Externí odkaz: